Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver cancer drug combo trial pulled before it started

NCT ID NCT06608940

Terminated Disease control Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to test a new experimental drug called BC3402 combined with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness were collected. The goal was to see if the combination could shrink tumors and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BC3402 (an experimental anti-TIM3 drug) combined with tremelimumab and durvalumab (immunotherapies)
What this could lead to
If it had worked, this combination might have offered a new treatment option for advanced liver cancer that hasn't responded to other therapies.
What could go wrong
The trial was withdrawn before enrolling anyone, so no results are available. Early-phase cancer trials often fail due to safety or lack of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATO CELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

  • Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.